
Silence Therapeutics (SLN) Stock Forecast & Price Target
Silence Therapeutics (SLN) Analyst Ratings
Bulls say
Silence Therapeutics is well-positioned in the biotech industry with promising therapies in multiple therapeutic areas. Its Divesiran therapy has a strong potential to address unmet needs in PV, with a high chance of success based on its mechanism of action and past clinical de-risking. With a favorable risk-benefit profile and a diverse pipeline, Silence Therapeutics is a compelling investment opportunity for those seeking exposure to the rapidly growing siRNA market.
Bears say
Silence Therapeutics is currently focused on developing products in three therapeutic areas, but there is not enough data to support the potential for success in any of these areas. The company's NPV analysis is based on conservative assumptions and partnerships, leaving much room for error. Additionally, its market cap remains low despite positive validation and Phase 1 data, indicating a lack of confidence in its potential success.
This aggregate rating is based on analysts' research of Silence Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Silence Therapeutics (SLN) Analyst Forecast & Price Prediction
Start investing in Silence Therapeutics (SLN)
Order type
Buy in
Order amount
Est. shares
0 shares